For research use only. Not for therapeutic Use.
BC-11 hydrobromide is a selective TMPRSS2 inhibitor (TMPRSS2 is a key host cellular factor for viral entry and SARS-CoV-2 pathogenesis), and a selective urokinase (uPA) inhibitor (IC50=8.2 μM). BC-11 hydrobromide is cytotoxic to triple-negative MDA-MB231 breast cancer cells. BC-11 hydrobromide is used in research on viral infections and cancer[1][2][3].
| Catalog Number | I010944 |
| CAS Number | 443776-49-6 |
| Synonyms | [4-(carbamimidoylsulfanylmethyl)phenyl]boronic acid;hydrobromide |
| Molecular Formula | C8H12BBrN2O2S |
| Purity | ≥95% |
| InChI | InChI=1S/C8H11BN2O2S.BrH/c10-8(11)14-5-6-1-3-7(4-2-6)9(12)13;/h1-4,12-13H,5H2,(H3,10,11);1H |
| InChIKey | PAFZAMOVHIRQOD-UHFFFAOYSA-N |
| SMILES | B(C1=CC=C(C=C1)CSC(=N)N)(O)O.Br |
| Reference | [1]. Moumbock AFA, et al. BC-11 is a covalent TMPRSS2 fragment inhibitor that impedes SARS-CoV-2 host cell entry. Arch Pharm (Weinheim). 2023 Jan;356(1):e2200371. [2]. Semina E, et al. Urokinase and urokinase receptor participate in regulation of neuronal migration, axon growth and branching. Eur J Cell Biol. 2016 Sep;95(9):295-310. [3]. Longo A, et al. Cytotoxicity of the Urokinase-Plasminogen Activator Inhibitor Carbamimidothioic Acid (4-Boronophenyl) Methyl Ester Hydrobromide (BC-11) on Triple-Negative MDA-MB231 Breast Cancer Cells. Molecules. 2015 May 28;20(6):9879-89. |
